Similar articles

• Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.

  Suzuki F, Suzuki Y, Akuta N, Sezaki H, Yatsuji H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Iwasaki S, Kumada H. Suzuki F, et al. J Clin Virol. 2010 Jan;47(1):76-8. doi: 10.1016/j.jcv.2009.09.029. Epub 2009 Oct 25. J Clin Virol. 2010. PMID: 19857995
• Telaprevir: hope on the horizon, getting closer.

  Weisberg IS, Jacobson IM. Weisberg IS, et al. Clin Liver Dis. 2009 Aug;13(3):441-52. doi: 10.1016/j.cld.2009.05.009. Clin Liver Dis. 2009. PMID: 19628160 Review.
• The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.

  Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G. Gentile I, et al. Expert Opin Investig Drugs. 2010 Jan;19(1):151-9. doi: 10.1517/13543780903501505. Expert Opin Investig Drugs. 2010. PMID: 20001560 Review.
• Long-term results of expansive open-door laminoplasty for cervical myelopathy--average 14-year follow-up study.

  Chiba K, Ogawa Y, Ishii K, Takaishi H, Nakamura M, Maruiwa H, Matsumoto M, Toyama Y. Chiba K, et al. Spine (Phila Pa 1976). 2006 Dec 15;31(26):2998-3005. doi: 10.1097/01.brs.0000250307.78987.6b. Spine (Phila Pa 1976). 2006. PMID: 17172996
• In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats.

  Maltais F, Jung YC, Chen M, Tanoury J, Perni RB, Mani N, Laitinen L, Huang H, Liao S, Gao H, Tsao H, Block E, Ma C, Shawgo RS, Town C, Brummel CL, Howe D, Pazhanisamy S, Raybuck S, Namchuk M, Bennani YL. Maltais F, et al. J Med Chem. 2009 Dec 24;52(24):7993-8001. doi: 10.1021/jm901023f. J Med Chem. 2009. PMID: 19894743